JUPITER NEUROSCIENCES, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
JUPITER NEUROSCIENCES, INC. (JUNS) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $491.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital › APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-14
- JUPITER NEUROSCIENCES, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $491.00K, a 6.16% increase year-over-year.
- JUPITER NEUROSCIENCES, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $454.24K, a 7.78% increase year-over-year.
- JUPITER NEUROSCIENCES, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $462.49K.
- JUPITER NEUROSCIENCES, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-03-31 was $421.45K.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month |
|---|---|---|
| 2026-06-30 | $491.00K 10-Q · filed 2026-08-14 | $945.24K derived: sum of 2 quarters · filed 2026-08-14 |
| 2026-03-31 | $454.24K 10-Q · filed 2026-08-14 | |
| 2025-06-30 | $462.49K 10-Q · filed 2026-08-14 | $883.94K derived: sum of 2 quarters · filed 2026-08-14 |
| 2025-03-31 | $421.45K 10-Q · filed 2026-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |